Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine
- 16 August 2018
- journal article
- letter
- Published by American Society of Hematology in Blood
- Vol. 132 (7), 761-764
- https://doi.org/10.1182/blood-2018-04-846493
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survivalBlood, 2018
- European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M–Related Light Chain AmyloidosisJournal of Clinical Oncology, 2016
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialThe Lancet, 2013
- Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosisLeukemia, 2012
- Treatment of IgM-Associated AL Amyloidosis With the Combination of Rituximab, Bortezomib, and DexamethasoneClinical Lymphoma Myeloma and Leukemia, 2011
- Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström's MacroglobulinemiaClinical Lymphoma Myeloma and Leukemia, 2011
- AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcomeBlood, 2008
- The Clinical Spectrum of IgM-Related AmyloidosisMedicine, 2008
- Autologous stem cell transplantation and IgM amyloidosisLeukemia & Lymphoma, 2006
- Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and AmyloidosisAmerican Journal of Hematology, 2005